JNJ 55308942

Drug Profile

JNJ 55308942

Alternative Names: JNJ-55308942

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen-Cilag
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy; Inflammation; Inflammatory bowel diseases; Mood disorders

Most Recent Events

  • 26 Feb 2018 Janssen-Cilag plans a phase I trial to investigate receptor occupancy of JNJ 55308942 in Healthy volunteers in Belgium (NCT03437590) (Trial profile 700293321)
  • 03 May 2017 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in Belgium (PO) (NCT03151486)
  • 03 May 2017 Phase-I clinical trials in Epilepsy (In volunteers) in Belgium (PO) (NCT03151486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top